Rallybio

RLYB · NASDAQ

$16.38+$0.03 (+0.18%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $16.35

RLYB analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jul 31, 2025

Bull case

The analysis indicates that Rallybio Corp has demonstrated promising Phase 1b proof-of-concept data for RLYB212, showcasing its potential to rapidly eliminate transfused, HPA-1a+ platelets, which suggests effectiveness in preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The successful dosing of the first pregnant woman at high risk of FNAIT is highlighted as a significant milestone, reflecting the potential acceptance and adoption of this treatment among expectant mothers facing severe challenges. Additionally, there is an acknowledgment of the company's strategic positioning due to the absence of any FDA-approved therapy for FNAIT, which enhances the likelihood of RLYB212 becoming a standard-of-care option in the future.

Bear case

Rallybio Corp reported a net loss of $0.25 per share, highlighting a lack of profitability in its current financial performance. The company faces significant risks, including potential delays in clinical trials for key pipeline candidates and the possibility of failing to produce favorable clinical data, particularly for its programs RLYB212 and RLYB116. Additionally, the company is exposed to partnership risks with entities such as Swedish Orphan Biovitrum AB, Exscientia PLC, and Sanofi S.A., along with concerns surrounding long-term dilution for shareholders.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.